文献速递血栓与止血

瓜氨酸化组蛋白H3作为中性粒细胞胞外诱捕网形成的生物标志物可预测癌症患者静脉血栓栓塞风险

Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.
PubMed 文献 · J Thromb Haemost · 2018-02-07

这项前瞻性观察性队列研究纳入946例新诊断或缓解后进展的癌症患者,检测入组时瓜氨酸化组蛋白H3(H3Cit)、游离DNA和核小体水平并随访2年。H3Cit水平升高(>分布第75百分位)与更高的静脉血栓栓塞(VTE)累积发生率相关,2年风险为14.5% vs 8.5%。竞争风险回归显示H3Cit每增加100 ng mL-1,VTE风险相对增加13%(SHR 1.13,95%CI 1.04-1.22)。

要点

  • H3Cit水平高于第75百分位的患者2年VTE累积风险为14.5%,低于该界值为8.5%。
  • H3Cit每升高100 ng mL-1,VTE风险相对增加13%(SHR 1.13,95%CI 1.04-1.22)。
  • 核小体和cfDNA升高与VTE风险的关联仅见于前3-6个月,呈时间依赖性。

核心结论

  • 这些数据提示中性粒细胞胞外诱捕网(NETs)形成的生物标志物与癌症患者VTE的发生相关,表明NETs在癌症相关血栓形成发病机制中可能起作用。

研究设计与样本

  • 前瞻性观察性队列研究,纳入946例新诊断癌症或缓解后进展的患者。
  • 入组时检测H3Cit、游离DNA(cfDNA)和核小体水平,随访2年。

主要发现

  • 89例患者发生VTE,3个月、6个月、12个月和24个月VTE累积发生率分别为3.7%、6.0%、8.1%和10.0%。
  • H3Cit水平高于其分布第75百分位(n=236)的患者2年VTE累积风险为14.5%,低于该界值(n=710)的患者为8.5%。
  • 竞争风险回归中,H3Cit每增加100 ng mL-1与VTE风险相对增加13%相关(SHR 1.13,95%CI 1.04-1.22)。
  • 校正高VTE风险和极高VTE风险肿瘤部位、D-二聚体水平及可溶性P-选择素水平后,该关联仍存在(SHR 1.13,95%CI 1.04-1.22)。
  • 核小体和cfDNA水平升高与VTE风险的关联呈时间依赖性,仅在前3-6个月与更高VTE风险相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Neutrophil extracellular traps (NETs) might play a role in cancer-related coagulopathy. We determined NET biomarkers and followed cancer patients for venous thromboembolism (VTE). We found a constant association with VTE for citrullinated histone H3. Biomarkers of NET formation could reflect a novel pathomechanism of cancer-related VTE. SUMMARY: Background Neutrophil extracellular traps (NETs) are decondensed chromatin fibers that might play a role in the prothrombotic state of cancer patients. Objectives To investigate whether the levels of citrullinated histone H3 (H3Cit), a biomarker for NET formation, cell-free DNA (cfDNA) and nucleosomes predict venous thromboembolism (VTE) in cancer patients. Patients/Methods Nine-hundred and forty-six patients with newly diagnosed cancer or progression after remission were enrolled in this prospective observational cohort study. H3Cit, cfDNA and nucleosome levels were determined at study inclusion, and patients were followed for 2 years. VTE occurred in 89 patients; the cumulative 3-month, 6-month, 12-month and 24-month incidence rates of VTE were 3.7%, 6.0%, 8.1%, and 10.0%, respectively. Results Patients with elevated H3Cit levels (> 75th percentile of its distribution, n = 236) experienced a higher cumulative incidence of VTE (2-year risk of 14.5%) than patients with levels below this cut-off (2-year risk of 8.5%, n = 710). In a competing-risk regression analysis, a 100 ng mL-1 increase in H3Cit level was associated with a 13% relative increase in VTE risk (subdistribution hazard ratio [SHR] 1.13, 95% confidence interval [CI] 1.04-1.22). This association remained after adjustment for high VTE risk and very high VTE risk tumor sites, D-dimer level, and soluble P-selectin level (SHR 1.13, 95% CI 1.04-1.22). The association of elevated nucleosome and cfDNA levels with VTE risk was time-dependent, with associations with a higher risk of VTE only during the first 3-6 months. Conclusion These data suggest that biomarkers of NET formation are associated with the occurrence of VTE in cancer patients, indicating a role of NETs in the pathogenesis of cancer-associated thrombosis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost. 2018. PMID: 29325226. doi:10.1111/jth.13951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。